 |
160 Products |  |
813 Diseases | | 160 Products |
|
1608 Trials |  |
78055 News |  |
| «12...879880881882883884885886887888889...903904» |
- |||||||||| Kanjinti (trastuzumab-anns) / Amgen, Daiichi Sankyo, AbbVie
New P3 trial: LILAC: Efficacy and Safety Study of ABP 980 Compared With Trastuzumab in Women With HER2-positive Early Breast Cancer (clinicaltrials.gov) - Jul 15, 2013
P3, N=808, Recruiting, Sponsor: Amgen
- Cosentyx (secukinumab) / Novartis
New P3 trial: Efficacy and Safety Study of Subcutaneous Secukinumab in Treatment of Subjects With Moderate to Severe Chronic Plaque-type Psoriasis as Compared to Etanercept and Placebo. (clinicaltrials.gov) - Jul 14, 2013
P3, N=0, Withdrawn, Sponsor: Novartis Pharmaceuticals
- ||||| Stivarga (regorafenib) / Bayer
New P2 trial, Metastases: REGO-SARC: Phase II Study of Regorafenib in Metastatic Soft Tissue Sarcoma (clinicaltrials.gov) - Jul 14, 2013
P2, N=192, Recruiting, Sponsor: Centre Oscar Lambret
- || trebananib (AMG 386) / Amgen
Enrollment closed: Safety Study of AMG 386 to Treat HER2-positive Locally Recurrent or Metastatic Breast Cancer (clinicaltrials.gov) - Jul 14, 2013
P1, N=65, Active, not recruiting, Sponsor: Amgen
Recruiting --> Active, not recruiting
- Neupogen (filgrastim) / Kyowa Kirin, Amgen
Combination therapy: Desipramine Hydrochloride and Filgrastim For Stem Cell Mobilization in Patients With Multiple Myeloma Undergoing Stem Cell Transplant (clinicaltrials.gov) - Jul 11, 2013
P=N/A, N=40, Recruiting, Sponsor: Albert Einstein College of Medicine of Yeshiva University
- ivabradine / Generic mfg.
Enrollment change: Promotion of Coronary Collateral Function by Ivabradine-Induced Bradycardia in Patients With Coronary Artery Disease (clinicaltrials.gov) - Jul 10, 2013
P=N/A, N=43, Completed, Sponsor: University Hospital Inselspital, Berne
Recruiting --> Active, not recruiting N=80 --> 43
- |||||||||| DiaPep277 / Evotec, Amgen
New P3 trial: DIA-AID 2: Open-Label Extension Study to Evaluate Long Term Safety and Treatment Effect of DiaPep277 (clinicaltrials.gov) - Jul 10, 2013
P3, N=300, Not yet recruiting, Sponsor: Andromeda Biotech Ltd.
- | Traficet-EN (vercirnon) / Amgen
Trial completion: Single and Repeat Dose Pharmacokinetic Study of GSK1605786 in Healthy Chinese Subjects (clinicaltrials.gov) - Jul 10, 2013
P1, N=21, Completed, Sponsor: GlaxoSmithKline
N=80 --> 43 Recruiting --> Completed
- ||||||| Quinsair (levofloxacin inhalational) / Chiesi, Amgen
Trial completion: Trial of Aeroquin Versus Tobramycin Inhalation Solution (TIS) in Cystic Fibrosis (CF) Patients (clinicaltrials.gov) - Jul 10, 2013
P3, N=267, Completed, Sponsor: Mpex Pharmaceuticals
Recruiting --> Completed Active, not recruiting --> Completed
- ||||||| Quinsair (levofloxacin inhalational) / Chiesi, Amgen
Trial completion: MP-376 (Aeroquin (clinicaltrials.gov) - Jul 10, 2013
P3, N=330, Completed, Sponsor: Mpex Pharmaceuticals
Active, not recruiting --> Completed Active, not recruiting --> Completed
- ivabradine / Generic mfg.
Trial completion: Promotion of Coronary Collateral Function by Ivabradine-Induced Bradycardia in Patients With Coronary Artery Disease (clinicaltrials.gov) - Jul 10, 2013
P=N/A, N=43, Completed, Sponsor: University Hospital Inselspital, Berne
Active, not recruiting --> Completed Recruiting --> Completed
- ||| Ravicti (glycerol phenylbutyrate) / Immedica, Amgen
Enrollment change: To Evaluate the Safety of Long-term Use of HPN-100 in the Management of Urea Cycle Disorders (UCDs) (clinicaltrials.gov) - Jul 9, 2013
P4, N=88, Active, not recruiting, Sponsor: Hyperion Therapeutics, Inc.
Recruiting --> Completed N=71 --> 88
- |||||||||| Parsabiv (etelcalcetide) / Amgen
New P3 trial, Head-to-Head: Head-to-Head Study of Etelcalcetide (AMG 416) and Cinacalcet (clinicaltrials.gov) - Jul 9, 2013
P3, N=600, Recruiting, Sponsor: Amgen
- | New P1/2 trial, Metastases: Phase I/II Study of SGI-110 With Irinotecan Versus Regorafenib or TAS-102 in Metastatic Colorectal Cancer (clinicaltrials.gov) - Jul 9, 2013
P1/2, N=108, Recruiting, Sponsor: Sidney Kimmel Comprehensive Cancer Center
- |||| Zolinza (vorinostat) / Merck (MSD)
Enrollment open, Combination therapy, Metastases: GemTax: Study of Vorinostat in Combination With Gemcitabine and Docetaxel in Advanced Sarcoma (clinicaltrials.gov) - Jul 9, 2013
P1/2, N=67, Recruiting, Sponsor: Hussein Tawbi
N=71 --> 88 Not yet recruiting --> Recruiting
- ||| Ravicti (glycerol phenylbutyrate) / Immedica, Amgen
Enrollment closed: To Evaluate the Safety of Long-term Use of HPN-100 in the Management of Urea Cycle Disorders (UCDs) (clinicaltrials.gov) - Jul 9, 2013
P4, N=88, Active, not recruiting, Sponsor: Hyperion Therapeutics, Inc.
Not yet recruiting --> Recruiting Enrolling by invitation --> Active, not recruiting
- ||||| DiaPep277 / Evotec, Amgen
Enrollment closed: DIA-AID2: Efficacy and Safety Study of DiaPep277 in Newly Diagnosed Type 1 Diabetes Adults (clinicaltrials.gov) - Jul 9, 2013
P3, N=450, Active, not recruiting, Sponsor: Andromeda Biotech Ltd.
Enrolling by invitation --> Active, not recruiting Recruiting --> Active, not recruiting
- || DiaPep277 / Evotec, Amgen
Trial completion: Long-Term Treatment Effect of DiaPep277 in Type 1 Diabetes (clinicaltrials.gov) - Jul 9, 2013
P3, N=43, Completed, Sponsor: Andromeda Biotech Ltd.
Recruiting --> Active, not recruiting Enrolling by invitation --> Completed
- ||||||| DiaPep277 / Evotec, Amgen
Trial completion: DIA-AID: Efficacy Study of DiaPep277 in Newly Diagnosed Type 1 Diabetes Patients (clinicaltrials.gov) - Jul 9, 2013
P3, N=457, Completed, Sponsor: Andromeda Biotech Ltd.
Enrolling by invitation --> Completed Active, not recruiting --> Completed
- Neulasta (pegfilgrastim) / Amgen, Kyowa Kirin, Roche
Trial completion, Metastases: Docetaxel, Cisplatin, Pegfilgrastim, and Erlotinib in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer (clinicaltrials.gov) - Jul 8, 2013
P2, N=45, Completed, Sponsor: Comprehensive Cancer Center of Wake Forest University
Active, not recruiting --> Completed Active, not recruiting --> Completed
- |||||| Evenity (romosozumab-aqqg) / Astellas, Amgen, UCB
Enrollment open: ARCH: Study to Determine the Efficacy and Safety of Romosozumab in the Treatment of Postmenopausal Women With Osteoporosis (clinicaltrials.gov) - Jul 7, 2013
P3, N=4000, Recruiting, Sponsor: Amgen
Active, not recruiting --> Completed Ongoing --> Recruiting
- ||| filanesib (ARRY-520) / Pfizer
Enrollment closed: A Study of ARRY-520 in Patients With Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov) - Jul 7, 2013
P1/2, N=80, Active, not recruiting, Sponsor: Array BioPharma
Ongoing --> Recruiting Recruiting --> Active, not recruiting
- | Prolia (denosumab) / Amgen
Biomarker, New P2 trial: Can treatment with drugs developed to treat thin and weakened osteoporotic bones make knee implants stay fixed in the bones and last longer? (EUDRACT) - Jul 2, 2013
P2, N=100, Ongoing, Sponsor: ORtop
- Erbitux (cetuximab) / Eli Lilly, tivantinib (ARQ 197) / Daiichi Sankyo, Kyowa Kirin, Merck (MSD)
New P2 trial: Study of Tivantinib (ARQ 197) Plus Cetuximab in EGFR Inhibitor-Resistant MET High Subjects (clinicaltrials.gov) - Jul 2, 2013
P2, N=41, Recruiting, Sponsor: Armando Santoro, MD
- Stivarga (regorafenib) / Bayer
Enrollment open: Pharmacokinetics and Safety of Regorafenib (BAY73-4506) in Cancer Subjects With Severe Renal Impairment (clinicaltrials.gov) - Jul 2, 2013
P1, N=35, Recruiting, Sponsor: Bayer
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- Leukine (sargramostim) / Partner Therap, Neupogen (filgrastim) / Kyowa Kirin, Amgen
Trial completion: Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Children With Relapsed Acute Lymphocytic Leukemia (clinicaltrials.gov) - Jul 2, 2013
P2, N=30, Completed, Sponsor: University of Nebraska
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- Vectibix (panitumumab) / Amgen
Enrollment closed: Paclitaxel, Carboplatin, and Panitumumab in Treating Patients With Metastatic Breast Cancer (clinicaltrials.gov) - Jul 1, 2013
P2, N=32, Active, not recruiting, Sponsor: Comprehensive Cancer Center of Wake Forest University
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- | Neulasta (pegfilgrastim) / Roche
Trial completion: Dose Dense TC + Pegfilgrastim Support for Breast Cancer (clinicaltrials.gov) - Jul 1, 2013
P2, N=41, Completed, Sponsor: University of Wisconsin, Madison
Recruiting --> Active, not recruiting Recruiting --> Completed
- Neupogen (filgrastim) / Kyowa Kirin, Amgen
Trial withdrawal, Metastases: Comparison of Immediate and Delayed Adjuvant Chemotherapy in Treating Patients Who Have Undergone a Radical Cystectomy for Stage III or Stage IV Transitional Cell Carcinoma of the Bladder Urothelium (clinicaltrials.gov) - Jun 30, 2013
P3, N=0, Withdrawn, Sponsor: National Cancer Institute (NCI)
Recruiting --> Completed Active, not recruiting --> Withdrawn
- Neupogen (filgrastim) / Kyowa Kirin, Amgen
Trial initiation date, Metastases: Comparison of Immediate and Delayed Adjuvant Chemotherapy in Treating Patients Who Have Undergone a Radical Cystectomy for Stage III or Stage IV Transitional Cell Carcinoma of the Bladder Urothelium (clinicaltrials.gov) - Jun 30, 2013
P3, N=0, Withdrawn, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Withdrawn Initiation date: Oct 2001 --> Jan 2005
- Neupogen (filgrastim) / Kyowa Kirin, Amgen
Enrollment change, Metastases: Comparison of Immediate and Delayed Adjuvant Chemotherapy in Treating Patients Who Have Undergone a Radical Cystectomy for Stage III or Stage IV Transitional Cell Carcinoma of the Bladder Urothelium (clinicaltrials.gov) - Jun 30, 2013
P3, N=0, Withdrawn, Sponsor: National Cancer Institute (NCI)
Initiation date: Oct 2001 --> Jan 2005 N=660 --> 0
- Enbrel (etanercept) / Pfizer, Amgen
Trial withdrawal: Human Tumor Necrosis Factor Alpha (TNFa)-Induced Pre-B Cell Bone Marrow Emigrants (clinicaltrials.gov) - Jun 29, 2013
P4, N=0, Withdrawn, Sponsor: University of Pittsburgh
N=660 --> 0 Recruiting --> Withdrawn
- Enbrel (etanercept) / Pfizer, Amgen
Enrollment change: Human Tumor Necrosis Factor Alpha (TNFa)-Induced Pre-B Cell Bone Marrow Emigrants (clinicaltrials.gov) - Jun 29, 2013
P4, N=0, Withdrawn, Sponsor: University of Pittsburgh
Recruiting --> Withdrawn N=12 --> 0
- bortezomib / Generic mfg.
Enrollment change, Combination therapy: AALL07P1: Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma (clinicaltrials.gov) - Jun 27, 2013
P2, N=60, Suspended, Sponsor: National Cancer Institute (NCI)
N=12 --> 0 N=150 --> 60
- | ivabradine / Generic mfg.
New P2 trial: Effects of ivabradine on vascular function in individuals at increased risk of developing cardiovascular disease and with impaired endothelial function (EUDRACT) - Jun 27, 2013
P2, N=340, Ongoing, Sponsor: Institut de Recherches Internationales Servier
- ||| Aimovig (erenumab-aooe) / Amgen, Novartis
New P1 trial: Study of Erenumab (AMG 334) in Women With Hot Flashes (clinicaltrials.gov) - Jun 27, 2013
P1, N=103, Active, not recruiting, Sponsor: Amgen
- ||||| Enrollment change, Metastases: High-Dose Combination Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Metastatic Rhabdomyosarcoma or Ectomesenchymoma (clinicaltrials.gov) - Jun 26, 2013
P3, N=109, Active, not recruiting, Sponsor: Children's Oncology Group
N=150 --> 60 N=75 --> 109
- |||| Prolia (denosumab) / Amgen, Daiichi Sankyo
Enrollment open: Study of Denosumab in Subjects With Giant Cell Tumor of Bone (clinicaltrials.gov) - Jun 26, 2013
P2, N=530, Recruiting, Sponsor: Amgen
N=75 --> 109 Active, not recruiting --> Recruiting
- Kepivance (palifermin) / SOBI, Amgen
Enrollment change, Surgery, Metastases: Palifermin in Lessening Oral Mucositis in Patients Undergoing Radiation Therapy and Chemotherapy for Locally Advanced Head and Neck Cancer (clinicaltrials.gov) - Jun 25, 2013
P3, N=21, Completed, Sponsor: Radiation Therapy Oncology Group
Active, not recruiting --> Recruiting N=298 --> 21
- ||||| Evrenzo (roxadustat) / FibroGen
New P2 trial: A Study to Investigate the Effect of ASP1517 After Intermittent Oral Dosing in Dialysis Chronic Kidney Disease Patients With Anemia Compared With Darbepoetin as a Reference Drug (clinicaltrials.gov) - Jun 25, 2013
P2, N=120, Active, not recruiting, Sponsor: Astellas Pharma Inc
- Neulasta (pegfilgrastim) / Roche
Enrollment change: G-CSF and Pegfilgrastim in Treating Neutropenia in Patients Undergoing Radiation Therapy and Chemotherapy for Limited Stage Small Cell Lung Cancer (clinicaltrials.gov) - Jun 24, 2013
P2, N=5, Completed, Sponsor: Radiation Therapy Oncology Group
N=298 --> 21 N=44 --> 5
- Epogen (epoetin alfa) / Amgen, Venofer (iron sucrose complex) / Daiichi Sankyo, CSL Behring
Enrollment open: The Benefits of a Preoperative Anemia Management Program (clinicaltrials.gov) - Jun 23, 2013
P=N/A, N=500, Recruiting, Sponsor: University of Alabama at Birmingham
N=44 --> 5 Not yet recruiting --> Recruiting
- ||||||| Epogen (epoetin alfa) / Amgen
Trial completion: A Randomized Trial of Procrit vs. No Procrit in AML and High Risk MDS (clinicaltrials.gov) - Jun 23, 2013
P3, N=51, Completed, Sponsor: M.D. Anderson Cancer Center
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- Stivarga (regorafenib) / Bayer
Trial termination, Combination therapy, Metastases: Determination of Safety, Efficacy, and Pharmacokinetics of "Regorafenib" Combined With Pemetrexed and Cisplatin in Patients With Nonsquamous Non-Small Cell Lung Cancer (clinicaltrials.gov) - Jun 22, 2013
P1, N=9, Terminated, Sponsor: Bayer
Active, not recruiting --> Completed Completed --> Terminated
- ||||| Xtoro (finafloxacin) / Amgen
Enrollment change: Safety and Efficacy Evaluation of Topical AL-60371 Otic Suspension, 0.3% in the Treatment of Acute Otitis Externa (clinicaltrials.gov) - Jun 20, 2013
P3, N=693, Completed, Sponsor: Alcon Research
Completed --> Terminated N=500 --> 693
- itacitinib (INCB039110) / Incyte
Enrollment open, Combination therapy, Metastases: Safety Study of Itacitinib (INCB039110) in Combination With Gemcitabine and Nab-Paclitaxel in Subjects With Advanced Solid Tumors (clinicaltrials.gov) - Jun 20, 2013
P1b, N=42, Recruiting, Sponsor: Incyte Corporation
N=500 --> 693 Not yet recruiting --> Recruiting
- ||| melphalan / Generic mfg., busulfan / Generic mfg.
Enrollment open: Busulfan, Melphalan, and Stem Cell Transplant After Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma (clinicaltrials.gov) - Jun 20, 2013
P=N/A, N=138, Recruiting, Sponsor: Children's Oncology Group
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- ||||||| Xtoro (finafloxacin) / Amgen
Trial completion: Safety and Efficacy Evaluation of Topical AL-60371 Otic Suspension, 0.3% in the Treatment of Acute Otitis Externa (clinicaltrials.gov) - Jun 20, 2013
P3, N=693, Completed, Sponsor: Alcon Research
Not yet recruiting --> Recruiting Recruiting --> Completed
- Traficet-EN (vercirnon) / Amgen
Trial withdrawal: A Study to Investigate the Efficacy and Safety of GSK1605786 for Treatment of Patients With Active Ulcerative Colitis (clinicaltrials.gov) - Jun 19, 2013
P2, N=0, Withdrawn, Sponsor: GlaxoSmithKline
Recruiting --> Completed Not yet recruiting --> Withdrawn
- Traficet-EN (vercirnon) / Amgen
Enrollment change: A Study to Investigate the Efficacy and Safety of GSK1605786 for Treatment of Patients With Active Ulcerative Colitis (clinicaltrials.gov) - Jun 19, 2013
P2, N=0, Withdrawn, Sponsor: GlaxoSmithKline
Not yet recruiting --> Withdrawn N=45 --> 0